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Abstract 
Due to urgency and demand, numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
immunoassays are rapidly being developed and placed on the market with limited validation on clinical 
samples. Thorough validation of serological tests are required to facilitate their use in the accurate diagnosis 
of SARS-CoV-2 infection, confirmation of molecular results, contact tracing, and epidemiological studies. This 
study evaluated the sensitivity and specificity of nine commercially available serological tests. These included 
three enzyme-linked immunosorbent assays (ELISAs) and six point-of-care (POC) lateral flow tests. The assays 
were validated using serum samples from: i) SARS-CoV-2 PCR-positive patients with a documented first day 
of disease; ii) archived sera obtained from healthy individuals before the emergence of SARS-CoV-2 in China; 
iii) sera from patients with acute viral respiratory tract infections caused by other coronaviruses or non-
coronaviruses; and iv) sera from patients positive for dengue virus, cytomegalovirus and Epstein Barr virus. 
The results showed 100% specificity for the Wantai SARS-CoV-2 Total Antibody ELISA, 93% for the Euroimmun 
IgA ELISA, and 96% for the Euroimmun IgG ELISA with sensitivities of 90%, 90%, and 65%, respectively. The 
overall performance of the POC tests according to manufacturer were in the rank order of AutoBio 
Diagnostics > Dynamiker Biotechnology = CTK Biotech > Artron Laboratories > Acro Biotech ≥ Hangzhou 
Alltest Biotech. Overall, these findings will facilitate selection of serological assays for the detection SARS-
CoV-2-specific antibodies towards diagnosis as well as sero-epidemiological and vaccine development 
studies. 
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Introduction 
In December 2019, a novel coronavirus causing severe acute respiratory symptoms emerged in Wuhan, China 
[1]. The World Health Organization (WHO) termed the disease, coronavirus disease 2019 (COVID-19), and 
the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 7 April, the virus has 
spread to 212 countries and territories with 1 279 722 confirmed cases and 72 614 deaths worldwide [2]. At 
present, the epidemic within the majority of countries have not yet reached its peak with the number of 
cases and deaths predicted to rise in the coming weeks and months. 
Accurate diagnosis of COVID-19 is essential, not only to ensure appropriate patient care but also to facilitate 
identification of SARS-CoV-2 infected people, including asymptomatic carriers, who need to be isolated to 
limit virus spread. The WHO recommends nucleic acid detection of SARS-CoV-2 in respiratory samples for the 
diagnosis of COVID-19. Unfortunately, in the face of the rapidly growing epidemics worldwide, an increased 
demand for diagnostic tests has led to a critical shortage in operational material for respiratory sample 
collection and within the molecular diagnostic workflow [3,4]. This impedes rapid large scale testing, a 
necessity for controlling the epidemic. Moreover, the heterogeneity of respiratory sample material and 
anatomical location of sample collection, for example throat swab, saliva or endotracheal aspirate, affect the 
sensitivity of SARS-CoV-2 viral nucleic acid testing [5,6]. Overall, there is an urgent need to identify alternative 
diagnostic means. 
Antibody testing, either using enzyme-linked immunosorbent assay (ELISA) or point-of-care (POC) lateral flow 
immunoassays, may overcome some of these challenges. SARS-CoV-2-specific antibodies can be detected in 
in serum of approximately 40% of COVID-19 patients as early as seven days after the onset of symptoms, 
with seroconversion rates rapidly increasing to >90% by day 14 [7]. In recent studies, antibody testing has 
been shown to be more sensitive than viral nucleic acid detection after approximately eight days of COVID-
19 illness duration [7,8]. While the combination of PCR and antibody tests is optimal for accurate diagnosis 
[6], antibody detection will be particularly relevant for the later stages of infection where the virus has been 
eliminated [5]. In addition to the diagnostic value of antibody testing, it will identify individuals who 
developed immunity after infection that may protect against subsequent re-infection [9], as well as define 
and monitor the extent of virus spread and a population’s herd immunity on a societal level. 
Antibody testing may therefore be relevant in the following settings: i) diagnosis of patients who seek medical 
attention more than seven after the onset of symptoms; ii) contact tracing; iii) determining potential 
immunity and risk of infection; and iv) sero-epidemiological studies to understand the extent of COVID-19 
spread. Due to urgency and demand, a lot of serological tests are rapidly being developed and made available 
on the market with only limited validation on clinical samples. To address this, the present study evaluated 
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three ELISA assays and six POC lateral flow immunoassays for the detection of SARS-CoV-2 antibodies in 
patients with COVID-19. CE-marked SARS-CoV-2 ELISA assays and POC tests were selected based on 
availability in Denmark at the time of testing. 
 
Materials & Methods 
Study design 
Retrospective study evaluating the sensitivity and specificity of commercially available immunoassays for the 
detection of antibodies specific to the SARS-CoV-2 virus. Patient serum samples used in this study were 
submitted to the routine serology laboratory at Statens Serum Institut for diagnostic purposes. 
Serum samples  
Case serum samples were obtained from COVID-19 patients (n = 30) admitted to the intensive care unit at 
Hillerød Hospital, Denmark. SARS-CoV-2 infection was confirmed by viral nucleic acid detection in samples 
from the respiratory tract. Control serum samples included archived anonymous serum samples obtained 
from healthy blood donors 18-64 years with no history of SARS-CoV-2 infection (n = 10) and no recent travel 
history, sera from patients with acute viral respiratory tract infections caused by other coronaviruses (n = 5) 
or non-coronaviruses (n = 45), and sera from patients positive for dengue virus (n = 9), cytomegalovirus (CMV; 
n = 2) and Epstein Barr virus (EBV; n = 10). One patient was positive for both CMV and EBV. 
ELISA assays 
The Wantai SARS-CoV-2 Ab ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China; Cat # WS-
1096) was performed according to the manufacturer’s instructions. The assay is based on a double-antigen 
sandwich principle that detects total antibodies binding SARS-CoV-2 spike protein receptor binding domain 
(RBD) in human serum or plasma. Briefly, 100 μl undiluted serum samples were added to wells coated with 
recombinant SARS-CoV-2 antigen and incubated for 30 minutes at 37 °C. Wells were washed five times 
followed by the addition of HRP-conjugated SARS-CoV-2 antigen and subsequent incubation for 30 minutes 
at 37 °C. Wells were washed five times and a chromogen solution was added. Following 15 minutes of 
incubation at 37 °C, the reaction was stopped and the resultant absorbance was read on a microplate reader 
at 450 nm with reference at 620 nm. The cut-off value for a positive result was calculated according to the 
manufacturer’s instruction by adding the calculated negative control value to 0.160. 
The Anti-SARS-CoV-2 IgG and IgA ELISAs (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany; Cat 
# EI 2668-9601 G and EI 2606-9601 A, respectively) were performed according to the manufacturer’s 
instructions. In two separate semi-quantitative ELISAs, either IgA or IgG antibodies against SARS-CoV-2 spike 
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protein subunit 1 (S1) are detected in human serum or plasma. Briefly, 1:101 diluted serum samples were 
added to wells coated with recombinant SARS-CoV-2 antigen and incubated for 60 minutes at 37 °C. Wells 
were washed three times followed by the addition of HRP-conjugated anti-human IgA or IgG and subsequent 
incubation for 30 minutes at 37 °C. Wells were washed three times and a chromogen solution was added. 
Following 30 minutes of incubation at room temperature, the reaction was stopped and the resultant 
absorbance was read on a microplate reader at 450 nm with reference at 620 nm. A ratio between the 
extinction of the sample and calibrator on each plate were calculated. According to the manufacturer’s 
recommendations, a ratio <0.8 is considered negative, ≥0.8 and <1.1 borderline, and ≥1.1 positive. However, 
for sensitivity and specificity, 1.1 was used as a more stringent cut-off value for positive results and all values 
<1.1 were considered negative. 
Point-of-care (POC) tests 
Six POC tests for rapid detection of antibodies in blood, serum or plasma were evaluated: 2019-nCOV IgG/IgM 
Rapid Test (Dynamiker Biotechnology, Tianjin, China Cat # DNK-1419-1), OnSiteTM COVID-19 IgG/IgM Rapid 
Test (CTK Biotech, Poway, CA, USA; Cat # R0180C), Anti-SARS-CoV-2 Rapid Test (AutoBio Diagnostics, 
Zhengzhou, China; Cat # RTA0204), Coronavirus Diseases 2019 (COVID-19) IgM/IgG Antibody Test (Artron 
Laboratories, Burnaby, Canada; Cat # A03-51-322), 2019-nCoV IgG/IgM Rapid Test Cassette (Acro Biotech, 
Rancho Cucamonga, CA, USA; Cat # INCP-402), and 2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou Alltest 
Biotech, Hangzhou, China; Cat # INCP-402). The tests were performed at room temperature according to the 
manufacturer’s instructions. For all tests, the recommended sample volume of 10 μl serum was added to the 
specimen well on the individual test cassettes followed by the addition of the supplied buffer. The buffer 
volume differed by manufacturer and was added accordingly (60 μl, three drops, two drops, two drops, two 
drops and 60 μl, respectively). The result was read visually after 10 minutes. Weak signals for IgM and IgG, 
together or separate, was considered positive. 
Statistical analyses 
Sensitivity was defined as the proportion of patients correctly identified as having SARS-CoV-2 infections, as 
initially diagnosed using nucleic acid detection of SARS-CoV-2 in respiratory samples. Specificity was defined 
as the proportion of SARS-CoV-2 immune naïve study participants accurately identified as negative for 
COVID-19. The clinical accuracies of the ELISA assays were examined by using Receiver Operator 
Characteristic (ROC) plots with GraphPad Prism version 8.0.2 (GraphPad Software, San Diego, CA, USA). ROC 
area under the curve (AUC) were calculated as the fraction “correctly identified to be positive” and the 
fraction “falsely identified to be positive” determined according to manufacturer cut-off values for positive 
results. 
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Results 
Sensitivities and specificities of the ELISA assays 
Three commercial CE-marked ELISA assays for detecting SARS-CoV-2 antibodies were evaluated using 30 
serum samples from PCR-positive cases with SARS-CoV-2 and 82 control serum samples. Twenty nine of the 
30 cases (97%) were positive for SARS-CoV-2-specific antibodies by at least one of the three ELISA assays. In 
one case, only a positive IgA result was detected, while in another case antibody responses were negative by 
all tests. 
The distance of data points from the manufacturer recommended cut-off values and confidence in assigning 
a positive or negative status differed between the three assays (Figure 1A). The distribution of positive and 
negative data points were distinct for the Wantai Total Ab assay, with a cut-off value above all the control 
sera samples, which allowed for unequivocal interpretation. Conversely, the Euroimmun IgA and IgG assays 
data had a less distinct separation, resulting in a ‘grey zone’ of borderline data points to which a positive or 
negative status could not be assigned. Both case and control sera had borderline or inconclusive data points.  
The sensitivities and specificities are shown in table 1. The sensitivity of the Wantai Total Ab ELISA was 
equivalent to that of Euroimmun’s IgA ELISA at 93% and was greater than that observed for Euroimmun’s IgG 
ELISA at 67%. The specificity of the Wantai Total Ab ELISA was 100% compared to 93% and 96% for the 
Euroimmun IgA and IgG ELISAs, respectively. The positive predictive value and negative predictive value was 
the highest for the Wantai Total Ab ELISA at 100% and 98%, respectively, compared to the Euroimmun IgA 
ELISA (82% and 97%, respectively) and IgG ELISA (87% and 89%, respectively). The Euroimmun IgA ELISA 
cross-reacted primarily with serum that contained antibodies to more than one respiratory virus (4/6 [67%]) 
and associated with the presence of adenovirus antibodies (5/6 [83%]) and dengue virus antibodies (Table 
2). The Euroimmun IgG ELISA cross-reacted with a serum sample positive for human coronavirus HKU1 and 
two samples with adenovirus antibodies. 
ROC analysis 
ROC AUC analysis presents a good parameter for the diagnostic power of an individual test and were 
compared between the different ELISA kits (Figure 1B). The Wantai total antibody kit had the highest measure 
at 0.973 (95% CI: 0.921-1.000), followed by Euroimmun’s IgA ELISA with 0.954 (95% CI: 0.897-1.00) and 
Euroimmun’s IgG ELISA with 0.887 (95% CI: 0.810-0.964). 
Sensitivities and specificities of the POC tests 
Four POC tests were tested on all 30 case serum samples and had sensitivities in the rank order of 93% for 
AutoBio Diagnostics, 90% Dynamiker Biotechnology and CTK Biotech, and 83% for Artron Laboratories (Table 
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1). The positive predictive value of these tests were 100%, while the negative predictive values were 91%, 
89%, 89%, and 74%, respectively. The Acro Biotech was evaluated on five case serum samples and had a 
specificity of 80%. One case serum sample was tested with the Hangzhou AllTest Biotech test and was positive 
for both IgM and IgG. 
The specificity of the six POC tests were evaluated primarily on control samples that showed some cross-
reactivity in the SARS-CoV-2 ELISA assays; the number of control sera tested varied between the different 
POC tests (Table 1). The POC tests manufactured by Dynamiker Biotechnology, CTK Biotech, AutoBio 
Diagnostics and Artron Laboratories had a 100% specificity, whereas the test from Acro Biotech and 
Hangzhou AllTest Biotech had a specificity of 80% and 87%, respectively. For the latter two tests, cross-
reactivity was only observed for IgM. The Acro Biotech test cross-reacted with a control serum sample from 
a human coronavirus HKU1 patient. 
Antibody detection relative to duration of illness 
To evaluate the sensitivities of the assays at different stages of COVID-19 disease, case sera were grouped 
according the duration of disease: early phase, 7 to 13 days after the onset of disease symptoms; middle 
phase, 14 to 20 days after the onset of disease symptoms; and late phase, ≥21 days after the onset of disease 
symptoms. The sensitivities of the assays ranged from 40 to 86% for the early phase samples, 67 to 100% for 
the middle phase samples, and 78 to 89% for the late phase (Figure 2). 
In the early phase, the Wantai Total Ab ELISA had a sensitivity of 71% that plateaued at 100% after 10 days 
of illness duration. The IgG ELISA had the lowest sensitivity at all three phases that showed a distinct increase 
with each consecutive phase i.e. 43% in the early phase, 67% in the middle phase, and 78% in the late phase. 
While the four POC tests evaluated according to illness duration were often weakly positive or detected only 
IgG or IgM during the early phase (data not shown), their sensitivities were comparable to the Wantai Total 
Ab ELISA and Euroimmun IgA ELISA in all three phases. In the early phase, a case sample that was negative 
by both Total Ab and IgG was positive in the IgA ELISA. 
Agreement between serological assays 
To determine the agreement between the different ELISAs and POC tests evaluate, the proportion of case 
sera that shared the same result between two assays were calculated. Despite comparable sensitivities of 
certain assays, the tests did not necessarily give the same result in all instances (Figure 3A). The only tests 
that were 100% concordant were the Dynamiker Biotechnology and CTK Biotech POC tests (Figure 3B). The 
Wantai Total Ab ELISA and Euroimmune IgA ELISA was 93% concordant, whereas the highest agreement 
between an ELISA and POC test was 93% between the Wantai Total Ab ELISA and AutoBio Diagnostics POC 
test. 
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Discussion 
In the present study, three SARS-CoV-2-specific commercial ELISA assays and six POC rapid tests were 
evaluated using sera from hospitalized adult patients with PCR-confirmed diagnoses for SARS-CoV-2 and a 
collection of control serum samples taken before the emergence of the virus in China in December 2019. 
Overall, the Wantai Total Ab ELISA had superior sensitivity and specificity compared to both Euroimmun IgA 
and IgG ELISAs. The POC tests varied notably, with the best performance observed for the test produced by 
AutoBio Diagnostics, followed by the tests produced by Dynamiker Biotechnology and CTK Biotech. 
The differences observed for the sensitivity and specificity of the SARS-CoV-2-specific total antibody testing 
and antibody type ELISAs correspond to previous reports. The Wantai Total Ab ELISA performed as reported 
by the manufacturer (94.5% sensitivity and 100% specificity) and a separate study (93.1% sensitivity) where 
the Total Ab ELISA, IgM ELISA and IgG ELISA produced by Beijing Wantai Biological Pharmacy Enterprise were 
compared [7]. In the latter study, the IgM and IgG ELISAs had lower sensitivities (83% and 65%, respectively) 
compared to the Total Ab ELISA (93.1%) [7]. This notably lower sensitivity for SARS-CoV-2-specific IgG 
detection is in agreement to that observed here for the Euroimmun IgG ELISA (65%). In the present study the 
Wantai IgG and Euroimmun IgG ELISAs could not be compared due to unavailability of the former. The 
possibility that overall lower sensitivity of SARS-CoV-2 IgG ELISAs may be a more universal occurrence rather 
than manufacturer dependent warrants further investigation. In addition to lower sensitivities, the 
Euroimmun IgA and IgG ELISAs are also more prone to cross-react with negative sera as described in the 
present study and in a separate analysis of the beta-versions of these assays [10]. 
The differences between the assays may, in part, be explained by the SARS-CoV-2 antigen targeted and the 
ELISA format used. Both kits detect antibodies to the S1 subunit of the SARS-CoV-2 spike protein; however, 
the Wantai Total Ab ELISA only targets the RBD within the S1. The RBD represents approximately 33% of the 
S1 subunit, thus epitopes that may be recognized by cross-reacting epitopes outside of this domain are 
absent. Furthermore, the RBD is highly diverse between SARS-CoV-2 and other beta-coronaviruses (hCoV-
OC43 and hCoV-HKU1), which may further reduce the likelihood of cross-reaction with these circulating 
coronaviruses. Moreover, the Wantai Total Ab ELISA uses an antigen-antibody-antigen(peroxidase) format 
whereas the Euroimmun ELISAs employ an antigen-antibody-antibody(peroxidase) format. The specificity of 
the former is determined by a single antibody, whereas the latter has a second antibody that may introduce 
additional specificities. The antigen-antibody-antibody format is required to distinguish between specific 
antibody types, but may not necessarily have lead to decreased specificity as shown for in-house ELISAs [10]. 
The clinical sensitivity of IgM for early diagnosis of COVID-19 is currently unclear. SARS-CoV-2-specific IgM 
does not consistently appear before its IgG counterpart, with some studies reporting detection of SARS-CoV-
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2 spike protein-specific IgG before IgM [6,7,11]. While all the POC tests evaluated in this study are capable of 
detecting both SARS-CoV-2 IgM and IgG antibodies, the majority detected both antibody types 
simultaneously, even in the early convalescent phase, while some detected only IgG and others only IgM 
(data not shown). On the contrary, cross-reactive IgM antibodies resulted in decreased specificity of two POC 
tests evaluated. This IgM-associated reduced specificity was not observed for all POC tests, thus other 
unknown factors define POC test specificity. POC tests are, by definition, often performed beside the patient, 
whereas ELISAs are conducted in laboratories. This study demonstrated that while certain ELISA assays and 
POC tests may share similar sensitivities and specificities, their results may not necessarily correspond for a 
single patient sample. These discrepancies should be noted where SARS-CoV-2 ELISAs are used to confirm 
POC test results. 
Since the appearance of antibodies is time dependent, diagnosis of COVID-19 by serological methods is 
limited to patients with a longer duration of illness. Within seven days of symptom onset or in the acute 
phase of disease, nucleic acid detection of SARS-CoV-2 in respiratory samples is superior to antibody 
detection for the diagnosis of COVID-19 [7,8,12]. However, after eight days of illness, the sensitivity of 
serological assays surpasses that of nucleic acid testing [7,8]. Here we reported a 100% seropositivity in 
patients 10 days after the onset of symptoms. It is unclear whether the latter sensitivity can be extrapolated 
to mild COVID-19 cases, since the present study comprised severely ill adult COVID-19 patients only. 
However, the sensitivity of the assay may not necessarily be very affected, since reports show similar 
seroconversion rates for patients with mild and severe COVID-19 disease despite generally lower SARS-CoV-
2 antibody titres in the former group [6,7,13]. Conversely, studies on the dynamics and detection of SARS-
CoV-2 antibodies in children are lacking and requires urgent attention. 
In conclusion, our findings show that in an ELISA format the sensitivity of detecting total SARS-CoV-2 RBD-
specific antibodies is higher than that of assays detecting spike-specific IgA or IgG only. It is important to note 
that the presence of SARS-CoV-2-specific antibodies does not necessarily correspond to protection against 
SARS-CoV-2 infection and disease. In order to define antibody-mediated protection, further investigation of 
virus-specific antibody functions that include neutralization and Fc-mediated effector functionality are 
needed. Sero-epidemiological investigations together with longitudinal studies on sequential samples taken 
from SARS-CoV-2 patients are necessary to characterize the spread of the virus and the long term protection 
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Tables 
TABLE 1. Analytical sensitivities, specificities, and predictive values for SARS-CoV-2 antibody detection 
  Number (%) of serum samples 
  
Assay 
Case sera testing 
positive 
Control sera testing 
negative 
 
PPV (%) NPV (%) 
      
ELISA      
Wantai Total Ab 28/30 (93) 82/82(100)  28/28 (100) 82/84 (98) 
Euroimmun IgAa 28/30 (93) 76/82 (93)  28/34 (82) 76/78 (97) 
Euroimmun IgGa 20/30 (67) 79/82 (96)  20/23 (87) 79/89 (89) 
      
Point-of-care test      
Dynamiker 27/30 (90) 32/32 (100)  27/27 (100) 32/36 (89) 
CTK Biotech 27/30 (90) 32/32 (100)  27/27 (100) 32/36 (89) 
AutoBio Diagnostics 28/30 (93) 32/32 (100)  28/28 (100) 32/25 (91) 
Artron Laboratories 25/30 (83) 17/17 (100)  25/25 (100) 17/23 (74) 
Acro Biotech 4/5 (80)b 12/15 (80)  4/7 (57) 12/13 (92) 
Alltest Biotech 1/1 (100)b 13/15 (87)  Too few tested Too few tested 
      
aBorderline data were considered negative. 
bDue to comparatively poorer assay performance in an initial round of testing, further testing were 
suspended. 
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TABLE 2. False positive results for sera from controls diagnosed with infections other than SARS-CoV-2 
 ELISA  Point-of-Care Tests 














Unknown 10  1   1  2   
hCoV-OC43 1       1   
hCoV-HKU1 2    1   2 1 (IgM only)  
hCoV-NL63 2       2   
Adv 4 1 1  1   1   
Infl A 5       0   
Infl B 7       0   
Infl A, Infl B 9  2     1   
Infl A, Infl B, Adv 6 1 2  1   3 1 (IgM only) 1 (IgM only) 
Infl A, Adv 4 1      1   
Infl B, Adv 2       1   
Infl A, Infl B, RSV 2       0   
Infl A, Infl B, RSV, Adv 3       2   
Adv, RSV 1 1      1   
Infl A, RSV, Adv 1 1      1   
Infl B, RSV 1       0   
EBV 10  2     0   
CMV 1       0   
CMV, EBV 2       0   
Dengue 9 1 1     2 1 (IgM only) 1 (IgM only) 
           
Total 82 6 9  3 1  20 3 2 
hCoV – human coronavirus; Adv – adenovirus; Infl – influenza; RSV – respiratory syncytial virus; EBV – 
Epstein-Barr virus; CMV – cytomegalovirus. 
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Figure 1. SARS-CoV-2 antibody ELISA assay performance. A) ELISA data distribution obtained for control 
and SARS-CoV-2 case sera using three commercial ELISA kits. Lines represents median values with 
interquartile ranges. The dotted lines indicate the respective cut-off values recommended by manufacturer 
to determine positive and negative test results. The grey zone marks the ratio range with borderline results. 
B) ROC curves for the respective ELISAS assays. 
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Figure 2. Analytical sensitivities of SARS-CoV-2 serologic assays in relation to the duration of illness: 7 to 
13 days (n = 7), 14 to 20 days (n = 15), and ≥21 days (n = 8). 
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Figure 3. Agreement between ELISA and POC test results. A) Individual COVID-19 patient with PCR-
confirmed SARS-CoV-2 infection. Each row represents a patient, each column a serological test, a blue block 
represents a positive result and a white block a negative result. B) The proportion of results that agreed 
between two assays. 
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